SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (1749)10/13/2005 9:37:38 AM
From: tuck  Read Replies (1) of 1784
 
Stratagene loses another legal round, tis time against Invitrogen:

>>CARLSBAD, Calif. (AP) -- Invitrogen Corp., a maker of genomics research equipment, said Thursday that an appeals court ruled in its favor in a patent infringement case brought against Stratagene Inc.

The appeal overturned a decision by a federal district court in Texas and ruled that Stratagene infringed a patent involving a process that allows bacteria to absorb foreign DNA, or become "competent."

Invitrogen said it offers 30 different types of competent cell products, which require obtaining a limited license for purchase. The company claimed that Stratagene never obtained a license for their competent cell products.

As a result, the case will go back to the district court level for continued proceedings.<<

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News